Global Standardization of Lipid/Lipoprotein Testing.

Area of Science:

• Clinical Chemistry
• Cardiovascular Diagnostics
• Biomarker Standardization

Background:

• Lipid and lipoprotein testing are crucial for atherosclerosis research, diagnosis, and management of dyslipidemia.
• A global standardization program for lipid testing was initiated by the CDC in 1988, establishing chemical methods as reference measurement procedures (RMPs).
• Concerns regarding the accuracy of direct LDL-C and HDL-C assays arose in 2010, creating clinical confusion.

Purpose of the Study:

• To evaluate the accuracy of direct LDL-C and HDL-C assays.
• To address confusion surrounding lipid assay performance.
• To investigate the shift towards mass spectrometry-based methods for lipoprotein standardization.

Main Methods:

• Comparative analytical studies of direct LDL-C and HDL-C assays.
• Evaluation of chemical reaction-based methods.
• Development of mass spectrometry-based methods for lipoprotein standardization.

Main Results:

• Comparative studies demonstrated that direct LDL-C and HDL-C assays are currently accurate enough for clinical use.
• Poor-performing reagents were removed from the market, improving overall assay quality.
• Reference measurement procedures are transitioning from chemical to mass spectrometry-based methods.

Conclusions:

• Direct LDL-C and HDL-C assays are sufficiently accurate for clinical application.
• Mass spectrometry-based methods are becoming the standard for lipoprotein measurement due to their accuracy and reduced technical demands.
• Standardization of lipoprotein(a) using mass spectrometry is an ongoing priority.